The ICER of birth-cohort screening with standard
treatment compared with risk-based screening was most
sensitive to the inclusion of QALY losses from disease
states before liver disease, the discount rate, and the
probability of an SVR given genotype 1 disease. For this
comparison, we estimated an ICER of $31 200 per
QALY saved when we assumed no QALY losses from
pre–liver disease states, $28 400 per QALY saved when
we assumed a discount rate of 5%, and $20 100 per
QALY saved when we assumed a 0.23 probability of an
SVR for those with genotype 1 disease who initiated
treatment (Figure 1).